Literature DB >> 20546501

The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.

B P Linas1, B Wang, M Smurzynski, E Losina, R J Bosch, B R Schackman, J Rong, P E Sax, R P Walensky, J Schouten, K A Freedberg.   

Abstract

HIV/hepatitis C virus (HCV) co-infection places a growing burden on the HIV/AIDS care delivery system. Evidence-based estimates of health services utilization among HIV/HCV co-infected patients can inform efficient planning. We analyzed data from the ACTG Longitudinal Linked Randomized Trials (ALLRT) cohort to estimate resource utilization and disability among HIV/HCV co-infected patients and compare them to rates seen in HIV mono-infected patients. The analysis included HIV-infected subjects enrolled in the ALLRT cohort between 2000 and 2007 who had at least one CD4 count measured and completed at least one resource utilization data collection form (N = 3143). Primary outcomes included the relative risk of hospital nights, emergency department (ED) visits, and disability days for HIV/HCV co-infected vs HIV mono-infected subjects. When controlling for age, sex, race, history of AIDS-defining events, current CD4 count and current HIV RNA, the relative risk of hospitalization, ED visits, and disability days for subjects with HIV/HCV co-infection compared to those with HIV mono-infection were 1.8 (95% CI: 1.3-2.5), 1.7 (95% CI: 1.4-2.1), and 1.6 (95% CI: 1.3-1.9) respectively. Programs serving HIV/HCV co-infected patients can expect approximately 70% higher rates of utilization than expected from a similar cohort of HIV mono-infected patients.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20546501      PMCID: PMC3347883          DOI: 10.1111/j.1365-2893.2010.01325.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  26 in total

1.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

3.  Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.

Authors:  Lisa I Backus; Barbara R Phillips; Derek B Boothroyd; Larry A Mole; Jane Burgess; Michael O Rigsby; Sophia W Chang
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-15       Impact factor: 3.731

4.  Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care.

Authors:  Catherine A Fleming; Sheila Tumilty; Jessica E Murray; David Nunes
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

Review 5.  Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS.

Authors:  A W Wu; R D Hays; S Kelly; F Malitz; S A Bozzette
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

6.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

7.  AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.

Authors:  Rochelle P Walensky; A David Paltiel; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2002-08-02       Impact factor: 9.079

8.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

9.  A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity.

Authors:  S A Bozzette; R D Hays; S H Berry; D E Kanouse
Journal:  Med Care       Date:  1994-07       Impact factor: 2.983

10.  Derivation and properties of a brief health status assessment instrument for use in HIV disease.

Authors:  S A Bozzette; R D Hays; S H Berry; D E Kanouse; A W Wu
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-03-01
View more
  22 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

Review 2.  Protease inhibitors for hepatitis C: economic implications.

Authors:  Stuart J Turner; Jack Brown; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

3.  Psychosocial correlates of HIV-monoinfection and HIV/HCV-coinfection among men who have sex with men.

Authors:  David W Pantalone; Danielle M Hessler; Sarah M Bankoff; Brijen J Shah
Journal:  J Behav Med       Date:  2011-09-23

4.  Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.

Authors:  Berkeley N Limketkai; Shruti H Mehta; Catherine G Sutcliffe; Yvonne M Higgins; Michael S Torbenson; Sherilyn C Brinkley; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  JAMA       Date:  2012-07-25       Impact factor: 56.272

Review 5.  HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.

Authors:  Lynn E Taylor; Tracy Swan; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2012-07       Impact factor: 9.079

6.  Hospitalization Trends and Comorbidities Among People With HIV/AIDS Compared With the Overall Hospitalized Population, Illinois, 2008-2014.

Authors:  Livia Navon
Journal:  Public Health Rep       Date:  2018-06-18       Impact factor: 2.792

Review 7.  Physical function, grip strength and frailty in people living with HIV in sub-Saharan Africa: systematic review.

Authors:  Charlotte Bernard; François Dabis; Nathalie de Rekeneire
Journal:  Trop Med Int Health       Date:  2017-03-08       Impact factor: 2.622

8.  Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.

Authors:  Benjamin P Linas; Angela Y Wong; Bruce R Schackman; Arthur Y Kim; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

Review 9.  Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation.

Authors:  Stephen E Congly; Karen E Doucette; Carla S Coffin
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

10.  Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection.

Authors:  Brianna L Norton; Lawrence Park; Leah J McGrath; Rae Jean Proeschold Bell; Andrew J Muir; Susanna Naggie
Journal:  AIDS Patient Care STDS       Date:  2012-08-03       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.